Funding for this research was provided by:
Received: 6 May 2019
Accepted: 19 June 2020
First Online: 23 June 2020
Ethics approval and consent to participate
: The study was approved by the Institutional Review Board of the Central Finland Health Care District. The use and investigation of the patient derived cells was conducted in accordance with approval by the local Ethics Committee of the Central Finland Health Care District (KSSHP 3 U/2015). All experiments were undertaken with the understanding and written informed consent of the patient. The study methodologies conformed to the standards set by the Declaration of Helsinki.
: Not applicable.
: The authors of this manuscript declare that they have no competing interests. Juha K. Rantala is the founder of Misvik Biology Oy.